Tiziana Life Sciences
TLSATLSA · Stock Price
Historical price data
Overview
Tiziana Life Sciences is a UK-based, Nasdaq-listed biotech focused on developing novel immunotherapies for neurodegenerative and neuroinflammatory diseases. Its core strategy leverages the intranasal delivery of foralumab, a fully human anti-CD3 monoclonal antibody, to achieve targeted CNS immunomodulation. The company has generated promising early clinical data in non-active Secondary Progressive Multiple Sclerosis and is rapidly expanding its clinical programs into Multiple System Atrophy, Alzheimer's, and ALS, supported by key collaborations with leading academic institutions like Brigham and Women's Hospital.
Technology Platform
Platform centered on intranasal delivery of a fully human anti-CD3 monoclonal antibody (foralumab) for targeted immunomodulation in the central nervous system.
Pipeline
14| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Milciclib Dose: 150 mg/day Mode of administration: oral | NSCLC | Phase 2 | |
| Foralumab | Secondary Progressive Multiple Sclerosis | Phase 2 | |
| Foralumab TZLS-401 50 µg + Foralumab TZLS-401 100 µg | Dementia | Phase 2 | |
| Foralumab | Covid19 | Phase 2 | |
| Foralumab TZLS-401 100 µg | Non-Active Secondary Progressive Multiple Sclerosis | Phase 2 |
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Competes in crowded neurodegenerative markets but is differentiated by its unique intranasal anti-CD3 mechanism aimed at modulating CNS neuroinflammation. Faces competition from approved MS therapies, anti-amyloid Alzheimer's drugs, and other neuroimmunology approaches, necessitating clear clinical differentiation.
Company Timeline
Founded in London, United Kingdom
Seed: $5.0M
IPO — $15.0M